



IFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 13, 2004

Signature: _____

(Li-Hsien Rin-Laures, M.D.)

Docket No.: 30610/30013A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Christopher M. Starr

Application No.: 10/658,699

Filed: May 1, 2000

Art Unit: 1632

For: Enzymes Useful for Treating and Methods for
Treating MPS-VI and Cell Lines for Producing Such
Enzymes Recombinantly

Examiner: To be assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the United States Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449 (Modified). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of documents B1 and C17-C18 are enclosed herewith. Copies of documents C1-C16 have been previously submitted to the Patent Office in U.S. Serial No. 09/562,427, from which priority is claimed under 35 U.S.C. §120. However, copies of these documents will be resubmitted at the Examiner's request.

This information disclosure statement is being submitted before the receipt of an official action. Accordingly, no fees are. Should the Patent Office determine that any further fees are due for consideration of this information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: July 13, 2004

Respectfully submitted,

By Li-Hsien Rin-Laures

Li-Hsien Rin-Laures, M.D.

Registration No.: 33,547

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket No.
30610/30013ASerial No.
10/658,699**INFORMATION DISCLOSURE
STATEMENT**Applicant
Christopher M. StarrFiling Date
September 9, 2003Group
1632**U.S. PATENT DOCUMENTS**

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	B1	WO 01/83722	11-08-2001	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Anson et al., "Correction of Human Mucopolysaccharidosis Type-VI Fibroblasts with Recombinant N-Acetylgalactosamine-4-Sulphatase," <i>Biochem J.</i> , 284:789-794 (1992).
C2	Bielicki et al., "Advantages of Using Same Species Enzyme for Replacement Therapy in a Feline Model of Mucopolysaccharidosis Type VI," <i>J. Biol. Chem.</i> , 274:36335-36343 (1999).
C3	Brooks et al., "Enzyme Replacement Therapy in Mucopolysaccharidosis VI: Evidence for Immune Response S and Altered Efficacy of Treatment in Animal Models," <i>Biochem. Biophys. Acta.</i> , 1361:203-216 (1997).
C4	Byers et al., "Effect of Enzyme Replacement Therapy on Bone Formation in a Feline Model of Mucopolysaccharidosis Type VI," <i>Bone</i> , 21:425-431 (1997).
C5	Crawley et al., "Enzyme Replacement Therapy from Birth in a Feline Model of Mucopolysaccharidosis Type VI," <i>J. Clin. Invest.</i> , 99:651-662 (1997).
C6	Crawley et al., "Enzyme Replacement Therapy from Birth in a Feline Model of Maroteaux-Lamy Syndrome," <i>J. Clin. Invest.</i> , 97:1864-1873 (1996).
C7	Haskins et al., "Spinal Cord Compression and Hindlimb Paresis in Cats with Mucopolysaccharidosis VI," <i>J. Am. Vet. Med. Assoc.</i> , 182:983-985 (1983).
C8	Haskins et al., "The Pathology of the Feline Model of Mucopolysaccharidosis VI," <i>Am. J. Pathol.</i> , 101:657-674 (1980).
C9	Hoogerbrugge et al., "Allogenic Bone Marrow Transplantation for Lysosomal Storage Diseases," <i>Lancet</i> , 345:1398-1402 (1995).
C10	Inherited Disease, eds., Scriver et al., New York:McGraw Hill, 1989, pp. 1565-1587.
C11	Jezyk et al., "Mucopolysaccharidosis in a Cat with Arylsulfatase B Deficiency: A Model of Maroteaux-Lamy Syndrome," <i>Science</i> , 198:834-836 (1977).
C12	Konde et al., "Radiographically Visualized Skeletal Changes Associated with Mucopolysaccharidosis VI in Cats," <i>Vet. Radiol.</i> , 28:223-228 (1987).
C13	Krivit et al., "Bone-Marrow Transplantation in the Maroteaux-Lamy Syndrome (Mucopolysaccharidosis Type VI)," <i>N. Eng. J. Med.</i> , 311:1606-1611 (1984).
C14	Peters et al., "Phylogenetic Conservation of Arylsulfatase," <i>J. Biol. Chem.</i> , 265:3374-3381 (1990).
C15	Roberts et al., "Development of a Procedure for Purification of a Recombinant Therapeutic Protein," <i>Australasian Biotechnol.</i> , 6:93-99 (1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 30610/30013A	Serial No. 10/658,699
INFORMATION DISCLOSURE STATEMENT		Applicant Christopher M. Starr	
		Filing Date September 9, 2003	Group 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C16	Yogalingam et al., "Regulation of N-Acetylglactosamine-4-Sulfatase Expression in Retrovirus-Transduced Feline Mucopolysaccharidosis Type VI Muscle Cells," <i>DNA Cell Biol.</i> , 18:187-195 (1999).	
C17	Krivit et al., "Maroteaux-Lamy Syndrome - Treatment b, Allogenic Bone Marrow Transplantation in 6 Patients and Potential for Antotransplantation Bone Marrow Gene Insertion," <i>Intl. Ped.</i> , 7:47-52 (1992).	
C18	McGovern et al., "Purification and Properties of Feline and Human Arylsulfatase B Isozymes," <i>J. Biol. Chem.</i> , 257:12605-12610 (1982).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	